Matching articles for "Eye"

In Brief: OTC Alcaftadine (Lastacaft Once Daily Relief) for Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • May 16, 2022;  (Issue 1650)
The ophthalmic H1-antihistamine alcaftadine 0.25%, which has been available by prescription since 2011 for use in patients with allergic conjunctivitis, is now available without a prescription as Lastacaft...
The ophthalmic H1-antihistamine alcaftadine 0.25%, which has been available by prescription since 2011 for use in patients with allergic conjunctivitis, is now available without a prescription as Lastacaft Once Daily Relief (Allergan) for temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair, and dander in adults and children ≥2 years old. It is the third ophthalmic antihistamine to be approved for over-the-counter (OTC) use (see Table 1).
Med Lett Drugs Ther. 2022 May 16;64(1650):78 | Show Full IntroductionHide Full Introduction

A Ranibizumab Ocular Implant (Susvimo) for Age-Related Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • May 2, 2022;  (Issue 1649)
The FDA has approved Susvimo (Genentech), a refillable permanent ocular implant containing the vascular endothelial growth factor (VEGF) inhibitor ranibizumab, for treatment of neovascular (wet)...
The FDA has approved Susvimo (Genentech), a refillable permanent ocular implant containing the vascular endothelial growth factor (VEGF) inhibitor ranibizumab, for treatment of neovascular (wet) age-related macular degeneration (nAMD) in patients who have previously responded to at least two intravitreal injections of a VEGF inhibitor. Ranibizumab intravitreal injection (Lucentis) has been available since 2006 for monthly treatment of nAMD. The FDA has approved ranibizumab-nuna (Byooviz), a biosimilar of Lucentis and the first ophthalmologic biosimilar; it will be available in June 2022.
Med Lett Drugs Ther. 2022 May 2;64(1649):71-2 | Show Full IntroductionHide Full Introduction

A Drug-Eluting Contact Lens for Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • April 18, 2022;  (Issue 1648)
The FDA has approved Acuvue Theravision with Ketotifen (Johnson & Johnson Vision Care), a daily-wear, disposable, vision-correcting soft contact lens that releases the H1-antihistamine ketotifen,...
The FDA has approved Acuvue Theravision with Ketotifen (Johnson & Johnson Vision Care), a daily-wear, disposable, vision-correcting soft contact lens that releases the H1-antihistamine ketotifen, for prevention of ocular itch due to allergic conjunctivitis in contact lens users. This is the first approval for a drug-eluting contact lens. Ketotifen eye drops (Alaway, Zaditor, and others) are available over the counter.
Med Lett Drugs Ther. 2022 Apr 18;64(1648):60-1 | Show Full IntroductionHide Full Introduction

Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema

   
The Medical Letter on Drugs and Therapeutics • March 21, 2022;  (Issue 1646)
Faricimab-svoa (Vabysmo – Genentech), an inhibitor of both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), has been approved by the FDA for intravitreal treatment of...
Faricimab-svoa (Vabysmo – Genentech), an inhibitor of both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), has been approved by the FDA for intravitreal treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). It is the first drug to become available in the US that targets two pathways involved in maintaining vascular homeostasis. Several VEGF inhibitors are available for treatment of nAMD and DME (see Table 2).
Med Lett Drugs Ther. 2022 Mar 21;64(1646):45-6 | Show Full IntroductionHide Full Introduction

Vuity - Pilocarpine Ophthalmic Solution for Presbyopia

   
The Medical Letter on Drugs and Therapeutics • February 7, 2022;  (Issue 1643)
The FDA has approved Vuity (Abbvie), a 1.25% ophthalmic solution of the muscarinic receptor agonist pilocarpine hydrochloride, for treatment of presbyopia in adults. Pilocarpine 1%, 2%, and 4% ophthalmic...
The FDA has approved Vuity (Abbvie), a 1.25% ophthalmic solution of the muscarinic receptor agonist pilocarpine hydrochloride, for treatment of presbyopia in adults. Pilocarpine 1%, 2%, and 4% ophthalmic solutions (Isopto Carpine, and others) have been available for years for treatment of glaucoma, but local and systemic adverse effects have limited their use.
Med Lett Drugs Ther. 2022 Feb 7;64(1643):17-8 | Show Full IntroductionHide Full Introduction

Teprotumumab (Tepezza) for Thyroid Eye Disease

   
The Medical Letter on Drugs and Therapeutics • May 31, 2021;  (Issue 1625)
Teprotumumab-trbw (Tepezza - Horizon), an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, has been approved by the FDA for IV treatment of thyroid eye disease. It is the first drug to be approved...
Teprotumumab-trbw (Tepezza - Horizon), an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, has been approved by the FDA for IV treatment of thyroid eye disease. It is the first drug to be approved in the US for this indication.
Med Lett Drugs Ther. 2021 May 31;63(1625):87-8 | Show Full IntroductionHide Full Introduction

Drugs for Allergic Rhinitis and Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • April 19, 2021;  (Issue 1622)
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table...
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2021 Apr 19;63(1622):57-64 | Show Full IntroductionHide Full Introduction

Durysta - A Bimatoprost Implant for Glaucoma

   
The Medical Letter on Drugs and Therapeutics • July 27, 2020;  (Issue 1603)
The FDA has approved an intracameral implant containing the prostaglandin analog bimatoprost (Durysta – Allergan) for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular...
The FDA has approved an intracameral implant containing the prostaglandin analog bimatoprost (Durysta – Allergan) for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Bimatoprost is also available in 0.01% (Lumigan) and 0.03% (generics) ophthalmic solutions for the same indication and in a 0.03% solution (Latisse, and generics) for eyelash enhancement. Durysta is the first ocular implant to become available in the US for treatment of glaucoma.
Med Lett Drugs Ther. 2020 Jul 27;62(1603):116-7 | Show Full IntroductionHide Full Introduction

Cetirizine Ophthalmic Solution (Zerviate) for Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • June 1, 2020;  (Issue 1599)
A 0.24% ophthalmic solution of the second-generation H1-antihistamine cetirizine (Zerviate – Eyevance) is now available by prescription for treatment of ocular itching associated with allergic...
A 0.24% ophthalmic solution of the second-generation H1-antihistamine cetirizine (Zerviate – Eyevance) is now available by prescription for treatment of ocular itching associated with allergic conjunctivitis in patients ≥2 years old. Oral cetirizine (Zyrtec, and others), which is used for treatment of allergic conjunctivitis and rhinitis, has been available over the counter (OTC) for years.
Med Lett Drugs Ther. 2020 Jun 1;62(1599):81-3 | Show Full IntroductionHide Full Introduction

Drugs for Common Eye Disorders

   
The Medical Letter on Drugs and Therapeutics • December 2, 2019;  (Issue 1586)
This issue includes reviews of drugs for glaucoma, age-related macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis is reviewed in a separate...
This issue includes reviews of drugs for glaucoma, age-related macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis is reviewed in a separate issue.
Med Lett Drugs Ther. 2019 Dec 2;61(1586):187-94 | Show Full IntroductionHide Full Introduction

Cannabis and Cannabinoids

   
The Medical Letter on Drugs and Therapeutics • November 18, 2019;  (Issue 1585)
Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of...
Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of cannabis. CBD, unlike THC, does not produce intoxication or euphoria.
Med Lett Drugs Ther. 2019 Nov 18;61(1585):179-82 | Show Full IntroductionHide Full Introduction

OTC Brimonidine (Lumify) for Ocular Redness

   
The Medical Letter on Drugs and Therapeutics • October 22, 2018;  (Issue 1558)
The FDA has approved an over-the-counter (OTC) 0.025% ophthalmic formulation of the selective alpha2-adrenergic agonist brimonidine tartrate (Lumify – Bausch & Lomb) for treatment of ocular redness...
The FDA has approved an over-the-counter (OTC) 0.025% ophthalmic formulation of the selective alpha2-adrenergic agonist brimonidine tartrate (Lumify – Bausch & Lomb) for treatment of ocular redness in adults and children ≥5 years old. Lumify is the first brimonidine product to be approved for OTC use.
Med Lett Drugs Ther. 2018 Oct 22;60(1558):176 | Show Full IntroductionHide Full Introduction

Two New Drugs for Glaucoma

   
The Medical Letter on Drugs and Therapeutics • July 16, 2018;  (Issue 1551)
The FDA has approved two new ophthalmic drugs for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension: latanoprostene bunod (Vyzulta – Bausch and Lomb), a...
The FDA has approved two new ophthalmic drugs for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension: latanoprostene bunod (Vyzulta – Bausch and Lomb), a modified prostaglandin analog, and netarsudil (VRhopressa – Aerie), the first Rho kinase inhibitor to be approved in the US.
Med Lett Drugs Ther. 2018 Jul 16;60(1551):117-20 | Show Full IntroductionHide Full Introduction

Voretigene Neparvovec-rzyl (Luxturna) for Inherited Retinal Dystrophy

   
The Medical Letter on Drugs and Therapeutics • March 26, 2018;  (Issue 1543)
The FDA has approved voretigene neparvovec-rzyl intraocular suspension (Luxturna – Spark), an adeno-associated virus vector-based gene therapy, for treatment of confirmed biallelic RPE65...
The FDA has approved voretigene neparvovec-rzyl intraocular suspension (Luxturna – Spark), an adeno-associated virus vector-based gene therapy, for treatment of confirmed biallelic RPE65 mutation-associated retinal dystrophy in patients who have viable retinal cells. It is the first gene replacement therapy approved in the US that targets a disease caused by mutations in a specific gene and the first pharmacologic treatment to be approved for this disorder.
Med Lett Drugs Ther. 2018 Mar 26;60(1543):53-5 | Show Full IntroductionHide Full Introduction

Riboflavin (Photrexa) and Ultraviolet Light for Progressive Keratoconus

   
The Medical Letter on Drugs and Therapeutics • June 19, 2017;  (Issue 1523)
The FDA has approved the ophthalmic solutions riboflavin 5'-phosphate in 20% dextran (Photrexa Viscous – Avedro) and riboflavin 5'-phosphate alone (Photrexa) for use with ultraviolet A (UVA) light (KXL...
The FDA has approved the ophthalmic solutions riboflavin 5'-phosphate in 20% dextran (Photrexa Viscous – Avedro) and riboflavin 5'-phosphate alone (Photrexa) for use with ultraviolet A (UVA) light (KXL System) in the corneal collagen cross-linking treatment of two corneal disorders: progressive keratoconus and corneal ectasia following refractive surgery. It is the first corneal collagen cross-linking (CXL) treatment to be approved by the FDA.
Med Lett Drugs Ther. 2017 Jun 19;59(1523):103-4 | Show Full IntroductionHide Full Introduction

Lifitegrast (Xiidra) for Dry Eye Disease

   
The Medical Letter on Drugs and Therapeutics • August 29, 2016;  (Issue 1502)
The FDA has approved a 5% ophthalmic solution of lifitegrast (Xiidra – Shire), a lymphocyte function-associated antigen-1 (LFA-1) antagonist, for treatment of the signs and symptoms of dry eye...
The FDA has approved a 5% ophthalmic solution of lifitegrast (Xiidra – Shire), a lymphocyte function-associated antigen-1 (LFA-1) antagonist, for treatment of the signs and symptoms of dry eye disease. Lifitegrast is the first LFA-1 antagonist to be approved for any indication in the US.
Med Lett Drugs Ther. 2016 Aug 29;58(1502):110-1 | Show Full IntroductionHide Full Introduction

New Treatments for Keratoconus

   
The Medical Letter on Drugs and Therapeutics • May 30, 2011;  (Issue 1365)
Keratoconus is a fairly common, progressive, noninflammatory, corneal-thinning disorder in which the cornea has a conical shape. Rigid gas permeable (RGP) contact lenses or corneal transplantation...
Keratoconus is a fairly common, progressive, noninflammatory, corneal-thinning disorder in which the cornea has a conical shape. Rigid gas permeable (RGP) contact lenses or corneal transplantation are effective treatments, but intracorneal ring segments and collagen cross-linking procedures offer some new alternatives in the management of the disease.
Med Lett Drugs Ther. 2011 May 30;53(1365):43-4 | Show Full IntroductionHide Full Introduction

Pegaptanib Sodium (Macugen) for Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • July 4, 2005;  (Issue 1212)
The FDA has approved pegaptanib sodium (Macugen - Pfizer/Eyetech) as an intravitreous injection for treatment of all subtypes of neovascular (wet) age-related macular degeneration (AMD). The only other approved...
The FDA has approved pegaptanib sodium (Macugen - Pfizer/Eyetech) as an intravitreous injection for treatment of all subtypes of neovascular (wet) age-related macular degeneration (AMD). The only other approved treatment for this condition is photodynamic therapy with intravenous verteporfin (Visudyne), which is recommended only for patients with one subtype (predominantly classic) of neovascular AMD.
Med Lett Drugs Ther. 2005 Jul 4;47(1212):55-6 | Show Full IntroductionHide Full Introduction

Viagra and Loss of Vision

   
The Medical Letter on Drugs and Therapeutics • June 20, 2005;  (Issue 1211)
The FDA recently announced that it was investigating 38 reports of loss of vision in men who took sildenafil (Viagra), which has been used to treat erectile dysfunction since...
The FDA recently announced that it was investigating 38 reports of loss of vision in men who took sildenafil (Viagra), which has been used to treat erectile dysfunction since 1998.
Med Lett Drugs Ther. 2005 Jun 20;47(1211):49 | Show Full IntroductionHide Full Introduction

Conductive Keratoplasty (CK) for Presbyopia

   
The Medical Letter on Drugs and Therapeutics • June 21, 2004;  (Issue 1185)
The ViewPoint CK System (Refractec) for conductive keratoplasty (CK), previously approved by the FDA as a device for treatment of hyperopia (farsightedness), was recently approved for treatment of presbyopia...
The ViewPoint CK System (Refractec) for conductive keratoplasty (CK), previously approved by the FDA as a device for treatment of hyperopia (farsightedness), was recently approved for treatment of presbyopia (age-associated loss of ability to view near objects).
Med Lett Drugs Ther. 2004 Jun 21;46(1185):49-50 | Show Full IntroductionHide Full Introduction

Corneal Surgery for Correction of Refractive Errors

   
The Medical Letter on Drugs and Therapeutics • December 17, 1999;  (Issue 1068)
...
All refractive corneal surgery reshapes the cornea to redirect light rays so that they focus on the retine....
Med Lett Drugs Ther. 1999 Dec 17;41(1068):122-3 | Show Full IntroductionHide Full Introduction

A Topical Carbonic Anhydrase Inhibitor For Glaucoma

   
The Medical Letter on Drugs and Therapeutics • September 1, 1995;  (Issue 956)
Dorzolamide hydrochloride (Trusopt - Merck), a thienothio-pyran-2-sulfonamide carbonic anhydrase inhibitor, was recently approved by the US Food and Drug Administration in a 2% ophthalmic solution for...
Dorzolamide hydrochloride (Trusopt - Merck), a thienothio-pyran-2-sulfonamide carbonic anhydrase inhibitor, was recently approved by the US Food and Drug Administration in a 2% ophthalmic solution for treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Med Lett Drugs Ther. 1995 Sep 1;37(956):76-7 | Show Full IntroductionHide Full Introduction

Corneal Surgery for Myopia

   
The Medical Letter on Drugs and Therapeutics • October 15, 1993;  (Issue 907)
Readers have inquired about the effectiveness and safety of operations on the cornea to correct refractive errors and restore normal vision without glasses or contact lenses. Several different operations are...
Readers have inquired about the effectiveness and safety of operations on the cornea to correct refractive errors and restore normal vision without glasses or contact lenses. Several different operations are now being used for this purpose.
Med Lett Drugs Ther. 1993 Oct 15;35(907):95-6 | Show Full IntroductionHide Full Introduction

Reading Machines For The Blind

   
The Medical Letter on Drugs and Therapeutics • February 21, 1992;  (Issue 864)
Electronic reading machines that convert print into speech have become increasingly useful for blind, other visually impaired, or dyslexic patients. Some of these devices are available as components that can...
Electronic reading machines that convert print into speech have become increasingly useful for blind, other visually impaired, or dyslexic patients. Some of these devices are available as components that can be added to a personal computer.
Med Lett Drugs Ther. 1992 Feb 21;34(864):13-4 | Show Full IntroductionHide Full Introduction

Metipranolol: A New Beta-blocker For Glaucoma

   
The Medical Letter on Drugs and Therapeutics • October 5, 1990;  (Issue 828)
Metipranolol hydrocholride 0.3% (OptiPranolol - Bausch & Lomb), a nonselective beta-adrenergic receptor blocking drug, was recently marketed of ophthalmic use to decrease intraolular pressure in ocular...
Metipranolol hydrocholride 0.3% (OptiPranolol - Bausch & Lomb), a nonselective beta-adrenergic receptor blocking drug, was recently marketed of ophthalmic use to decrease intraolular pressure in ocular hypertension or chronic open-angle glaucoma. Beta-blockers available in the USA for treatment of glaucoma are listed in this article.
Med Lett Drugs Ther. 1990 Oct 5;32(828):91-2 | Show Full IntroductionHide Full Introduction

Soft Contact Lenses

   
The Medical Letter on Drugs and Therapeutics • July 27, 1990;  (Issue 823)
Soft contact lenses have been in use for more than 20 years. Since the last Medical Letter review (vol. 24, page 109, 1982), new products have been developed, and some problems have...
Soft contact lenses have been in use for more than 20 years. Since the last Medical Letter review (vol. 24, page 109, 1982), new products have been developed, and some problems have emerged.
Med Lett Drugs Ther. 1990 Jul 27;32(823):69-70 | Show Full IntroductionHide Full Introduction